Day One Biopharmaceuticals’ (DAWN) “Hold” Rating Reaffirmed at JonesTrading

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “hold” rating reissued by equities researchers at JonesTrading in a report issued on Friday,Benzinga reports. They currently have a $21.50 price target on the stock, up from their prior price target of $20.00. JonesTrading’s target price would indicate a potential upside of 1.37% from the company’s current price.

A number of other equities analysts have also recently commented on the company. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Friday. Zacks Research downgraded Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their price objective on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. HC Wainwright reduced their target price on shares of Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals presently has an average rating of “Hold” and a consensus target price of $25.56.

Day One Biopharmaceuticals Stock Performance

Shares of Day One Biopharmaceuticals stock traded up $8.43 on Friday, hitting $21.21. 76,023,164 shares of the company traded hands, compared to its average volume of 4,312,633. Day One Biopharmaceuticals has a 52 week low of $5.64 and a 52 week high of $21.23. The business has a 50-day simple moving average of $10.87 and a 200 day simple moving average of $8.95. The stock has a market capitalization of $2.19 billion, a P/E ratio of -20.59 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). The firm had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. Research analysts expect that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Adam Dubow sold 6,395 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $74,182.00. Following the completion of the sale, the insider owned 72,694 shares of the company’s stock, valued at approximately $843,250.40. This represents a 8.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael Vasconcelles sold 2,728 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $31,644.80. Following the transaction, the insider directly owned 4,397 shares in the company, valued at approximately $51,005.20. The trade was a 38.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 36,461 shares of company stock worth $422,948. 6.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after buying an additional 1,029 shares during the period. Federated Hermes Inc. acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth about $39,000. Quarry LP acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth about $49,000. Ameritas Investment Partners Inc. grew its stake in Day One Biopharmaceuticals by 44.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after purchasing an additional 2,264 shares during the last quarter. Finally, CWM LLC increased its holdings in shares of Day One Biopharmaceuticals by 32.4% in the fourth quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after purchasing an additional 2,051 shares during the period. Institutional investors own 87.95% of the company’s stock.

Key Stories Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Servier agreed to acquire Day One for $21.50 per share in cash, implying a total equity value of ~ $2.5B; transaction expected to close in Q2 subject to customary conditions — a clear liquidity event and floor price for shareholders. Read More.
• Positive Sentiment: Market reaction was strong: shares surged on the buyout news and there was a large uptick in call-option activity (20,759 calls traded, ~519% above average), consistent with heavy bullish positioning around the deal. Read More.
• Positive Sentiment: Analyst commentary highlighting Day One’s commercial momentum (OJEMDA growth) and upcoming clinical milestones remains supportive of intrinsic value beyond the deal price, which could influence investor sentiment on alternative bidders or negotiations. Read More.
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement for “news pending,” a routine market-protection measure that preceded the deal release.
• Neutral Sentiment: Needham reaffirmed a “hold” rating on the stock — a reminder some analysts still see limited upside versus the deal price absent alternate bidders or a higher offer. Read More.
• Negative Sentiment: Multiple law firms (Ademi LLP, Halper Sadeh LLC, Monteverde & Associates) have launched investigations and potential class-action claims alleging the buyout may not provide a fair price, which could lead to litigation, delay closing or pressure terms. Read More. Read More. Read More.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.